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original work is propObjective(s): An HIV cure will impose aviraemia that is sustained following the
withdrawal of antiretroviral therapy (ART). Understanding the efficacy of novel inter-
ventions aimed at curing HIV requires characterization of both natural viral control and
the effect of ART on viral control after treatment interruption.
Design: Analysis of transient viral control in recent seroconverters in the Short Pulse
AntiRetroviral Therapy at Acute Seroconversion trial.
Methods: We compared untreated and treated HIV seroconverters (n¼292) and ident-
ified periods of control (plasma HIV RNA<400 copies/ml for 16 weeks off therapy) in
7.9%of ART-naive participants, and in 12.0%overall. HIVDNAwasmeasured by qPCR,
andHIV-specificCD8þ responsesweremeasuredbyenzyme-linked immunosorbent spot
assay (ELISpot). T-cell activation and exhaustion were measured by flow cytometry.
Results: At baseline, future controllers had lower HIV DNA, lower plasma HIV RNA,
higher CD4þ : CD8þ ratios (all P<0.001) and higher CD4þ cell counts (P<0.05) than
noncontrollers. Among controllers, the only difference between the untreated and those
who received ART was higher baseline HIV RNA in the latter (P¼0.003), supporting an
added ART effect.
Conclusion: Consideration of spontaneous remission in untreated individuals will be
critical to avoid overestimating the effect size of new interventions used in HIV cure
studies. Copyright  2017 Wolters Kluwer Health, Inc. All rights reserved.AIDS 2017, 31:477–484Keywords: antiretroviral therapy, ELISpot, HIV, HIV DNA, natural history,
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478 AIDS 2017, Vol 31 No 4IntroductionStrategies to achieve an HIV cure by implementing
interventions to deplete the HIV reservoir – a pool of
latently infected cells containing transcriptionally
repressed viral DNA – are entering clinical trials. In
the absence of a validated biomarker to prove cure, a key
outcome measure in these studies is the time to detection
of viral RNA, or ‘viral rebound’, in plasma after stopping
antiretroviral therapy (ART) in an analytic treatment
interruption [1–5].
Patients with primary HIV infection (PHI) are of
particular interest, as with lower reservoir sizes [6–9]
and preserved immunity [6,10–13] with less immune
escape [14–16], there may be increased prospect of
achieving remission. ART alone, when initiated during
PHI, may induce remission, as described for post-
treatment controllers (PTCs) in the VISCONTI cohort
[17]. However, to understand the impact of ART – or
any other intervention – on remission requires charac-
terization of the time from seroconversion to a detectable
HIV plasma viral load in untreated patients. Treatment of
PHI is now recommended in revised international clinical
guidelines [18,19] meaning that randomized trials with a
‘no treatment’ arm cannot be undertaken. As such, we
must turn to high-quality historical data to assist
interpretation of treatment interruption studies.
The ‘Short Pulse AntiRetroviral Therapy at Acute
Seroconversion’ (SPARTAC) trial [20,21] was a random-
ized controlled trial of 0, 12 or 48 weeks of ART initiated
during PHI. The study design provided the unusual
opportunity to compare viral load dynamics in treated
and untreated seroconverters. We turned to SPARTAC to
understand whether reports of PTC and virological
remission following treatment interruption might be
conflated by natural transient delays to detectable
viraemia in untreated seroconverters.Methods
Participants and trial design
SPARTAC (EudraCT number: 2004-000446-20) was a
multicentre randomized controlled trial of short-course
ART (12 or 48 weeks ART, vs no immediate ART)
initiated during PHI [20]. For all analyses, baseline refers
to the date of randomization. Of 366 participants, 74
were excluded for logistical reasons, leaving 292
participants who were included in this analysis. Partici-
pants were assessed according to whether they received 12
or less vs more than 12 weeks ART, compared with no
immediate ART. This same 12 week cut-off was used in a
previous ‘as received’ analysis of SPARTAC [22].
Within this ‘at risk’ group, we identified controllers who
experienced a period of remission which was defined for Copyright © 2017 Wolters Kluwer Hall as HIV RNA less than 400 copies/ml, on two
measurements at least 16 weeks apart, with the period of
remission starting within 1 year of randomization or ART
cessation (untreated and treated groups, respectively). We
included participants who experienced a viral blip of any
magnitude at a single time point. Time of viral rebound
was the first of at least two consecutive measurements
more than 400 copies/ml.
HIV DNA quantification
Total HIV DNA was quantified at baseline (where there
were sufficient samples available; n¼ 200) by a previously
described qPCR assay [21,23].
CD8R T-cell ELISpot assays
HIV Gag-specific CD8þ T-cell responses were measured
by IFN-g ELISpot assays to overlapping peptides using
methods described elsewhere [24,25].
Flow cytometry
The expression of exhaustion (PD-1, Tim-3 and Lag-3)
and activation [CD25, CD38, CD69 and human
leucocyte antigen (HLA) DR] markers on CD4þ and
CD8þ T cells was measured on cryopreserved samples
(refer to Supplemental Digital Content 1 for antibodies
used, http://links.lww.com/QAD/B35). Data were
acquired on a MacsQuant Analyser (Miltenyi, Bergisch
Gladbach, Germany) and analysed using FlowJo Version
10.0.7 or 10.8.0r1 (Treestar, Ashland, Oregon, USA).
Statistical analyses
Categorical variables were compared using x2 or Fisher–
Freeman–Halton exact test as appropriate. Continuous
variables were compared across three groups using the
Kruskal–Wallis test or analysis of variance (ANOVA).
Pairwise comparisons were made using Mann–Whitney
or Student’s t test. Duration of viral control was assessed
using Kaplan–Meier estimates. For all tests, P values less
than 0.05 were considered statistically significant.
Analyses were performed using R version 3.2.2. Plots
were drawn using GraphPad Prism (GraphPad Software,
La Jolla, California, USA) version 6.0f.Results and Discussion
Transient control of viraemia is evident in
untreated primary HIV infection
Most studies of virological control have focused on ‘elite’
and PTCs [17,26,27]. We set out to explore a different
question – are there individuals who experience transient
viral control during untreated PHI, and how does this
compare with post-ART remission?
Our analysis included 292 of 366 participants recruited to
the SPARTAC trial who had sufficient HIV RNA
sampling and, if treated, were virologically suppressed
prior to treatment interruption. Time on ART is analysedealth, Inc. All rights reserved.
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and stratified as 0, 12 or less or more than 12 weeks of
ART. Throughout this analysis, HIV RNA measure-
ments less than 400 copies/ml are considered ‘suppressed’
as this was the lower limit of detection for assays
conducted at South African and Ugandan trial sites. As
such, this was the lowest HIV RNA threshold that could
be applied across all samples.
Considering these participants, regardless of ARTuse, 35
of 292 (12.0%) experienced a period of suppressed
viraemia (HIV RNA< 400 copies/ml) of at least 16
weeks while off therapy and are termed ‘controllers’ for
this report. Of the 126 participants who did not receive
immediate ART, 10 (7.9%) experienced a period of
spontaneous viral control within 1 year of randomization.
Among individuals who received short-course ART
(n¼ 80 12 weeks; n¼ 86> 12 weeks) and underwent
treatment interruption, 25 (15.1%) experienced viral
remission in the subsequent year.
PTCs have been almost exclusively identified among
individuals who initiated ART during PHI, suggesting an
impact of early ARTon long-term viral control [17]. We
found some evidence of greater frequency of control in
individuals who had received more than 12 weeks ART,
when compared across all three groups, although this was
not statistically significant (P¼ 0.06; Table 1). In the best
characterized cohort of PTCs to date (VISCONTI),
patients received a median of 3 years ART prior to
treatment interruption [17]. Twelve weeks of ART is
likely to be too short to induce durable PTC, and it is
possible that the participants who received 12 weeks or
less ART in this analysis were more similar to untreated
controllers than those who received more than 12 weeks
ART (as also indicated by the primary outcome analysis of
SPARTAC, which was based on clinical progression
[20]). Accordingly, we performed all comparisons across
the three groups rather than combining the two ART
arms. Of note, if the 12 week or less group was excluded
from the analysis of control, there were significantly more
controllers following ART compared with no treatment
(18.6% vs 7.9%; P¼ 0.03). In our previous analysis of
viral rebound in only the treated participants in
SPARTAC, longer treatment duration was significantly
associated with slower viral rebound within 12 weeks of
stopping ART consistent with these findings [22].
A strength of this analysis is the ability to quantify viral
remission among treated and untreated individuals with
PHI in a well characterized and frequently sampled
randomized study. Several studies of ART initiated during
PHI have demonstrated the presence of individuals who
transiently control viral replication post-treatment inter-
ruption [30–35]. None of these previous studies included
an untreated arm, thus limiting their ability to evaluate
the added impact of ART on the presence of transient
viral control. An analysis of the Quest study (in which Copyright © 2017 Wolters Kluweparticipants underwent treatment interruption following
at least 72 weeks ART initiated during PHI) [32] used
data from untreated individuals from a separate PHI
cohort (CASCADE) as controls. That analysis showed no
significant difference in the frequency of transient viral
control between the two studies [36], although a different
HIV RNA cut-off (1000 copies/ml) and duration of
analysis were used.
Duration of remission in treated and untreated
controllers
We next looked to see whether the duration of viral
control varied between controllers who did or did not
receive ART. There were more participants with over 1
year of remission among those receiving more than 12
weeks ART compared with 12 weeks or less or no ART
[13 (15.1% of all participants) vs 3 (3.8%) vs 8 (6.3%),
respectively (Table 1)]. Eight controllers (five of whom
had received>12 weeks ART) experienced undetectable
HIV RNA until the end of follow-up [median 192 weeks
(interquartile range 165–202)]. There was, however, no
statistically significant difference between the duration of
remission between the three groups when including the
full duration of follow-up (P¼ 0.22; log rank). Interest-
ingly, when just considering the controllers, untreated
participants were more likely to experience sustained
control more than 104 weeks (7/10) compared with the
treated controllers for whom rebound was more evenly
distributed over the assessment period, and which may
have implications for the underlying mechanisms.
Controllers have more favourable baseline
clinical characteristics than noncontrollers
In comparison with the noncontrollers (regardless of
treatment group), future controllers had more favourable
baseline clinical characteristics with higher CD4þ T-cell
counts (median 700 vs 557 cells/ml), lower plasma HIV
RNA (median 2.70 vs 4.59 log10 copies/ml), higher
CD4þ-to-CD8þ ratio (median 0.77 vs 0.52) and lower
total HIV DNA [mean 3.35 vs 3.85 log10 copies/10
6
CD4þ T cells (Fig. 1a–d; Table, Supplemental Digital
Content 2 contains values, http://links.lww.com/QAD/
B35)]. These findings are consistent with previous studies
of viral control during PHI with [30,33,34,37] and
without [38,39] treatment.
Spontaneous controllers have lower baseline HIV
RNA than those who received more than 12
weeks antiretroviral therapy
When focusing on just the controllers, untreated
participants had similar baseline CD4þ cell counts,
CD4þ : CD8þ ratios and HIV DNA levels to those who
controlled following treatment interruption, but had
significantly lower baseline HIV RNA than those who
had received more than 12 weeks ART [median 2.30 vs
3.82 log10 copies/ml, respectively (P¼ 0.002; Fig. 1b;
Table, Supplemental Digital Content 2, http://
links.lww.com/QAD/B35)]. The interval betweenr Health, Inc. All rights reserved.
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Table 1. Characteristics of controllers identified in Short Pulse AntiRetroviral Therapy at Acute Seroconversion.
Total, n¼292 12 weeks ART, n¼80 >12 weeks ART, n¼86 No ART, n¼126 P value
No. of controllers (% total
participants)
35 (12.0) 9 (11.3) 16 (18.6) 10 (7.9) 0.06
Duration of short course ART
[weeks; median (IQR)]
– 11.9 (11.8–12.0) 47.8 (47.3–47.9) – –
Interval between estimated
serconversion and
randomization [days; median
(IQR)]
– 92.0 (64.0–106) 97.5 (58.0–125) 95.5 (76.8–116) 0.64
Viral subtype 0.16
B 13 2 6 5
C 18 5 10 3
Other (A1, B/C, B/F and D) 4 2 0 2
Countrya 0.38
South Africa/Uganda 20 6 10 4
United Kingdom 11 3 3 5
Other (Australia/Brazil) 4 0 3 1
Sex 1
Male 13 3 6 4
Female 22 6 10 6
Age [years; median (IQR)] – 40 (25–47.5) 27.5 (21.3–46.5) 32 (26–35.5) 0.33
HLA alleles b
1 protective class I allele 11 1 7 3 0.54
1 disease-susceptible class I
allele
11 5 5 1 0.08
BM35 : 01 allele 2 0 2 0 –
Duration of remission (weeks) –
<26 1 0 0 1
26–52 10 6 3 1
52–104 8 0 7 1
>104 16 3 6 7
No. without viral rebound at end of
follow-up
8 (2.7) 1 (1.3) 5 (5.8) 2 (1.6) –
Statistical tests were performed across all three groups. Categorical variables, including number of controllers, were compared using x2 test or
Fisher–Freeman–Halton exact test as appropriate; continuous variables were compared using Kruskal–Wallis test. IQR, interquartile range.
Duration of remission was calculated between date of randomization (untreated arm) or ART cessation (treated arms) and viral rebound. ART,
antiretroviral therapy. Protective class I alleles were defined as BM27 : 05, BM57 : 01 for subtype B and BM57 : 02, BM57 : 03, BM81 : 01, BM58 : 01 for
subtype C. Disease-susceptible class I alleles were defined as BM35 : 01, BM07 : 02 for subtype B and BM58 : 02, BM18 : 01 for subtype C [24,28,29].
aNo controllers were identified from Ireland, Spain or Italy.
bAnalysis performed for participants with subtype B or C virus only.seroconversion and baseline was similar between treat-
ment groups and did not explain this finding (Table 1).
This difference in baseline HIV RNA supports an
additional impact of ART in inducing viral remission in
some individuals who otherwise may not control viral
replication, providing evidence for post-treatment con-
trol as a distinct phenomenon.
Similar demographics and immunological
characteristics in antiretroviral therapy–
receiving and spontaneous controllers.
Next, we compared the demographic and immunological
characteristics of untreated and treated controllers
(n¼ 35). We found no evidence for demographic
differences between untreated and treated controllers in
terms of sex, viral subtype, country of origin and age
(Table 1). Because CD8þ T-cell responses are associated
with clinical progression [40] and drive durable
spontaneous (or ‘elite’) control, we looked for the
presence of protective HLA Class I alleles amongst
controllers identified in this study. The proportion of Copyright © 2017 Wolters Kluwer Hcontrollers with protective or disease-susceptible HLA
Class I alleles was similar between treatment groups. Two
controllers carried HLA B35 alleles, which has been
observed amongst PTCs in the VISCONTI case series
[17]. As a measure of CD8þ recognition of HIV, we
measured CD8þ T-cell responses to HIV peptides by
Gamma Interferon ELISpot. We assessed responses across
HIV Gag, which did not differ between treated and
untreated controllers and were similar in breadth (Fig. 1e)
and magnitude (Fig. 1f) to those measured in noncon-
trollers. The percentage of CD4þ and CD8þ T cells
expressing markers of exhaustion (PD-1, Tim-3 and Lag-
3) and activation (HLA-DR, CD69, CD25 and CD38) at
baseline also did not differ between treatment groups
(data not shown).Conclusion
There are two key findings to this analysis. One is the
demonstration of long periods of transient viral remissionealth, Inc. All rights reserved.
 Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.
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Fig. 1. Clinical characteristics of controllers identified in Short Pulse AntiRetroviral Therapy at Acute Seroconversion. Baseline
clinical variables of controllers (three groups shown with open circles) and noncontrollers (green, shaded circles) identified in
Short Pulse AntiRetroviral Therapy at Acute Seroconversion. Bars shown indicate the mean (SD) for total HIV DNA (d) and median
(interquartile range) for all other parameters (a–c, e, f). CD4þ cell count (a), viral load (b), CD4þ to CD8þ ratio [(C) all total
n¼292], as well as breadth (e) and magnitude [(F) both total n¼145] of CD8þ responses across Gag were compared between
noncontrollers and combined controller groups using the Mann–Whitney test. Total HIV DNA [(d) total n¼ 200] was compared
between these two groups using Student’s t test. Comparisons between three controller groups were made using Kruskal–Wallis
(a–c, e, f) and ANOVA (d) tests. For viral load, this was significantly different (P¼0.006), and pairwise comparisons shown (b)
were made between groups using the Mann–Whitney test. P<0.05.
482 AIDS 2017, Vol 31 No 4in a substantial proportion of untreated individuals after
PHI, which may conflate data from those who transiently
control after ART interruption. The second finding
confirms previous reports of beneficial baseline charac-
teristics associated with future virological control and
supports an additional impact of ART during PHI.
Following the results of the START trial, which provided
evidence of clear clinical benefit in starting ART
irrespective of CD4þ cell count [41], untreated controls
cannot be included in future HIV trial protocols. The use
of uncontrolled treatment interruption studies to measure
the success of potentially curative strategies means that
modest delays in viral rebound may be attributed to an
intervention. Accordingly, consideration of spontaneous
remission in PHI will be critical to avoid overestimating
the effect size of interventions used in treatment
interruption studies.Acknowledgements
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